China Approves World's First Invasive BCI Medical Device for Hand Function Restoration

China's regulatory authority has approved an invasive brain-computer interface (BCI) system designed to help patients with paralysis regain hand movement.

This approval marks a major milestone, potentially making it the world's first formally approved invasive BCI device for this specific rehabilitation purpose.

The decision is the culmination of China's systematic efforts, including strategic government policies, the establishment of industry standards, and prior clinical research.

China has taken a significant leap in the field of neurotechnology, potentially marking a world-first achievement.

China's National Medical Products Administration (NMPA) has reportedly approved an invasive Brain-Computer Interface (BCI) system from Shanghai-based Borui Kang Medical. This device is designed to help patients with paralysis due to cervical spine injuries regain the ability to grasp objects. If officially confirmed, this would be the world's first formal market approval for an invasive BCI aimed at restoring hand function, moving the technology from research trials to real-world clinical application.

This development is particularly noteworthy when compared to the global landscape. In the U.S., while Neuralink garnered headlines for its first human implant in early 2024, it is still in the clinical trial phase and has not received market approval. The FDA did approve a non-invasive BCI for hand rehabilitation called IpsiHand back in 2021, but Borui Kang's device is invasive, meaning it involves a surgically implanted component, representing a different technological and regulatory challenge.

So, how did this breakthrough happen? It wasn't a sudden event but the result of a deliberate, multi-year strategy. First, the Chinese government has provided strong policy support, officially designating BCI as a key 'future industry' to be nurtured. This creates a favorable environment for both research and commercialization. Second, regulators laid the groundwork by establishing clear standards. In early 2026, China's first industry standard for BCI medical devices (YY/T 1987-2025) came into effect, defining terminology and classifications. This standardization provides a clear roadmap for companies and streamlines the review process for regulators.

Third, the NMPA had prior experience with similar technologies. In late 2025, it approved an invasive deep brain stimulation (DBS) system for treating addiction, which, while for a different purpose, built regulatory expertise in reviewing invasive neural interfaces. Finally, Borui Kang itself has been on a fast track, having its device enter the NMPA's 'special review channel' for innovative devices, which accelerates the approval timeline.

However, it's important to approach this news with a degree of caution. As of mid-March 2026, the official NMPA announcement with a registration number has not been publicly released. Final confirmation is still needed by checking the NMPA's official database. Still, this development signals that China is not just a participant but a potential leader in the race to bring advanced neurotechnology to patients.

BCI (Brain-Computer Interface): A system that reads brain signals and translates them into commands for an external device, allowing a person to control it with their thoughts.
NMPA (National Medical Products Administration): China's main regulatory body for drugs and medical devices, equivalent to the FDA in the United States.
Invasive BCI: A type of BCI that requires a device to be surgically implanted inside the body, such as on or in the brain, to read neural signals with high precision.

China Approves World's First Invasive BCI Medical Device for Hand Function Restoration

China's regulatory authority has approved an invasive brain-computer interface (BCI) system designed to help patients with paralysis regain hand movement.

This approval marks a major milestone, potentially making it the world's first formally approved invasive BCI device for this specific rehabilitation purpose.

The decision is the culmination of China's systematic efforts, including strategic government policies, the establishment of industry standards, and prior clinical research.

China has taken a significant leap in the field of neurotechnology, potentially marking a world-first achievement.

BCI (Brain-Computer Interface): A system that reads brain signals and translates them into commands for an external device, allowing a person to control it with their thoughts.
NMPA (National Medical Products Administration): China's main regulatory body for drugs and medical devices, equivalent to the FDA in the United States.
Invasive BCI: A type of BCI that requires a device to be surgically implanted inside the body, such as on or in the brain, to read neural signals with high precision.